Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US

Alzheimer's disease

(2021) Philip Scheltens et al.   LANCET

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of Aducanumab for Alzheimer Disease

(2021) G. Caleb Alexander et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

(2021) Jeffrey Cummings et al.   Alzheimers Research & Therapy

Critical Appraisal of Amyloid Lowering Agents in AD

(2021) Boris Decourt et al.   Current Neurology and Neuroscience Reports

Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?

(2021) Kevin A. Schulman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks

(2021) David S. Knopman et al.   NEUROLOGY

Revisiting FDA Approval of Aducanumab

(2021) G. Caleb Alexander et al.   NEW ENGLAND JOURNAL OF MEDICINE

Approval of Aducanumab for Alzheimer Disease—the FDA’s Perspective

(2021) Billy Dunn et al.   JAMA Internal Medicine

Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab

(2021) Francis J. Crosson et al.   JAMA Internal Medicine

Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019

(2020) Alexandra Erath et al.   JAMA Network Open

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

(2020) Thomas K. Karikari et al.   MOLECULAR PSYCHIATRY

Estimates of the Association of Dementia With US Mortality Levels Using Linked Survey and Mortality Records

(2020) Andrew C. Stokes et al.   JAMA Neurology

How Much Value Would a Treatment for Alzheimer’s Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy

(2020) Hankyung Jun et al.   Current Alzheimer Research

The Real-World Medicare Costs of Alzheimer Disease: Considerations for Policy and Care

(2019) Bruce Pyenson et al.   Journal of Managed Care & Specialty Pharmacy

Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study

(2019) Jin-Tai Yu et al.   Alzheimers & Dementia

Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling framework

(2019) Colin Green et al.   Alzheimers & Dementia

In-hospital outcomes and 30-day readmission rates among ischemic and hemorrhagic stroke patients with delirium

(2019) Farhaan S. Vahidy et al.   PLoS One

Value-Based Pricing for Drugs

(2018) Anna Kaltenboeck et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]

(2018) Darius N. Lakdawalla et al.   VALUE IN HEALTH

Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting

(2018) Rosebud O. Roberts et al.   JAMA Neurology

Dementia-Associated Mortality at Thirteen Years in the NEDICES Cohort Study

(2018) Alberto Villarejo et al.   JOURNAL OF ALZHEIMERS DISEASE

Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged ≥65 years

(2018) Kevin A. Matthews et al.   Alzheimers & Dementia

How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer’s disease?

(2017) Catherine Reed et al.   Health and Quality of Life Outcomes

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

(2016) Gillian D. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Unknown

(2016)   ACTA PSYCHIATRICA SCANDINAVICA

ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures

(2014) Jeffrey L. Anderson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Contribution of Alzheimer disease to mortality in the United States

(2014) B. D. James et al.   NEUROLOGY

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

(2014) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monetary Costs of Dementia in the United States

(2013) Michael D. Hurd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Measuring Alzheimer Disease Progression with Transition Probabilities: Estimates from NACC-UDS

(2012) D. Eldon Spackman et al.   Current Alzheimer Research

How Cancer Patients Value Hope And The Implications For Cost-Effectiveness Assessments Of High-Cost Cancer Therapies

(2012) Darius N. Lakdawalla et al.   HEALTH AFFAIRS

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Predictors of costs of care in Alzheimer’s disease: A multinational sample of 1222 patients

(2011) Anders Gustavsson et al.   Alzheimers & Dementia

Multicomponent Geriatric Intervention for Elderly Inpatients With Delirium: Effects on Costs and Health-Related Quality of Life

(2011) K. H. Pitkala et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores

(2008) Sid E. O’Bryant   ARCHIVES OF NEUROLOGY